1-9 of 9
John R. Desjarlais
Close
Sort by
Journal Articles

Immunotherapy with Long-Lived Anti-CD123 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD123+ Cells in Monkeys: A Potential Therapy for Acute Myelogenous Leukemia

Seung Y. Chu, PhD, Erik Pong, MS, Hsing Chen, MS, Sheryl Phung, MS, Emily W. Chan, BS, Nancy A. Endo, BS, Rumana Rashid, PhD, Christine Bonzon, PhD, Irene W.L. Leung, PhD, Umesh S. Muchhal, PhD, Gregory L. Moore, PhD, Matthew J. Bernett, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD
Journal: Blood
Blood (2014) 124 (21): 2316.
https://doi.org/10.1182/blood.V124.21.2316.2316
Published: 2014
Journal Articles

Immunotherapy with Long-Lived Anti-CD20 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and Leukemias

Seung Y. Chu, PhD, Sung-Hyung Lee, PhD, Rumana Rashid, PhD, Hsing Chen, MS, Emily W. Chan, BS, Sheryl Phung, MS, Erik Pong, MS, Nancy A. Endo, BS, Yvonne Miranda, MS, Christine Bonzon, PhD, Irene W.L. Leung, PhD, Umesh S. Muchhal, PhD, Gregory L. Moore, PhD, Matthew J. Bernett, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD
Journal: Blood
Blood (2014) 124 (21): 3111.
https://doi.org/10.1182/blood.V124.21.3111.3111
Published: 2014
Journal Articles

Immunotherapy with Long-Lived Anti-CD38 × Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+ Cells in Monkeys: A Potential Therapy for Multiple Myeloma

Seung Y. Chu, PhD, Yvonne Miranda, MS, Sheryl Phung, MS, Hsing Chen, MS, Rumana Rashid, PhD, Nancy A. Endo, BS, Emily W. Chan, BS, Erik Pong, MS, Christine Bonzon, PhD, Umesh S. Muchhal, PhD, Irene W.L. Leung, PhD, Matthew J. Bernett, PhD, Gregory L. Moore, PhD, David E. Szymkowski, PhD, John R. Desjarlais, PhD
Journal: Blood
Blood (2014) 124 (21): 4727.
https://doi.org/10.1182/blood.V124.21.4727.4727
Published: 2014
Journal Articles

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function

Yu-Tzu Tai, Holly M. Horton, Sun-Young Kong, Erik Pong, Hsing Chen, Saso Cemerski, Matthew J. Bernett, Duc-Hanh T. Nguyen, Sher Karki, Seung Y. Chu, Greg A. Lazar, Nikhil C. Munshi, John R. Desjarlais, Kenneth C. Anderson, Umesh S. Muchhal
Journal: Blood
Blood (2012) 119 (9): 2074–2082.
https://doi.org/10.1182/blood-2011-06-364521
Published: 2012
Includes: Supplemental data
Journal Articles

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

Holly M. Horton, Matthew J. Bernett, Matthias Peipp, Erik Pong, Sher Karki, Seung Y. Chu, John O. Richards, Hsing Chen, Roland Repp, John R. Desjarlais, Eugene A. Zhukovsky
Journal: Blood
Blood (2010) 116 (16): 3004–3012.
https://doi.org/10.1182/blood-2010-01-265280
Published: 2010
Journal Articles

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

Farrukh T. Awan, Rosa Lapalombella, Rossana Trotta, Jonathan P. Butchar, Bo Yu, Don M. Benson, Jr, Julie M. Roda, Carolyn Cheney, Xiaokui Mo, Amy Lehman, Jeffrey Jones, Joseph Flynn, David Jarjoura, John R. Desjarlais, Susheela Tridandapani, Michael A. Caligiuri, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2010) 115 (6): 1204–1213.
https://doi.org/10.1182/blood-2009-06-229039
Published: 2010
Journal Articles

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates

Jonathan Zalevsky, Irene W. L. Leung, Sher Karki, Seung Y. Chu, Eugene A. Zhukovsky, John R. Desjarlais, David F. Carmichael, Chris E. Lawrence
Journal: Blood
Blood (2009) 113 (16): 3735–3743.
https://doi.org/10.1182/blood-2008-10-182048
Published: 2009
Journal Articles

XmAb®5574, An Fc Engineered Humanized Anti-CD19 Monoclonal Antibody, Has Potent in Vitro and in Vivo Activities, and Has the Potential for Treating B Cell Malignancies

Chris E Lawrence, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Irene Leung, PhD, Seung Chu, PhD, Sher Karki, PhD, Eugene Zhukovsky, PhD, John R Desjarlais, PhD, David F Carmichael, PhD
Journal: Blood
Blood (2008) 112 (11): 2621.
https://doi.org/10.1182/blood.V112.11.2621.2621
Published: 2008
Journal Articles

XmAb™2513, an Fc Engineered Humanized Anti-CD30 Monoclonal Antibody, Has Potent In Vitro and In Vivo Activities, and Has the Potential for Treating Hematologic Malignancies.

Chris E. Lawrence, PhD, Phil W. Hammond, PhD, Jonathan Zalevsky, PhD, Holly Horton, PhD, Seung Chu, PhD, Sher Karki, PhD, John R. Desjarlais, PhD, David F. Carmichael, PhD
Journal: Blood
Blood (2007) 110 (11): 2340.
https://doi.org/10.1182/blood.V110.11.2340.2340
Published: 2007